Serina Therapeutics (SER) director gets 10,000 options at $3.91
Serina Therapeutics (SER) reported a director equity grant.
Rhea-AI Filing Summary
Serina Therapeutics (SER) reported a director equity grant. On 11/07/2025, a stock option (right to buy) for 10,000 shares was awarded at an exercise price of $3.91 per share, coded A for grant. The option expires on 11/07/2035 and was recorded as Direct (D) ownership with 10,000 derivative securities beneficially owned after the transaction.
The options vest on the earlier of the day before the next Annual Meeting or the one-year anniversary of the grant date, subject to the director’s continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 10,000 shares
Grant/Award
1 txn
Insider
Bailey Gregory
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 10,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 10,000 contracts (Direct)
Footnotes (1)
- F1. The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
FAQ
How many options were granted to the SER director?
A stock option for 10,000 shares was granted.
What is the exercise price of the SER director’s options?
The exercise price is $3.91 per share.
When were the options granted to the SER director?
The transaction date is 11/07/2025.
When do the SER director’s options expire?
The options expire on 11/07/2035.
What is the vesting schedule for the SER director’s options?
They vest on the earlier of the day before the next Annual Meeting or the one-year anniversary of the grant date, subject to continued service.
What transaction code applies to the SER option grant?
The transaction is coded A (grant).
What ownership form is reported for the options?
Ownership is reported as Direct (D) with 10,000 derivative securities beneficially owned after the transaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.